Alanyl-glutaminyl-glycyl-valine clinical trials
Also written EA-230 and AQGV.
How each study uses alanyl-glutaminyl-glycyl-valine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the alanyl-glutaminyl-glycyl-valine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Radboud University Medical Center (2) · EBI Anti Sepsis BV (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test alanyl-glutaminyl-glycyl-valine, phase 3 first.
Studies
Open first, then newest update. How each study uses alanyl-glutaminyl-glycyl-valine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.RecruitingPhase 3EBI Anti Sepsis BVNCT07357675Written as EA-230 90mg/kg/hour
- Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)Status unknownPhase 2Radboud University Medical CenterNCT03145220Written as EA-230
- PK/PD of EA-230 During EndotoxemiaCompletedPhase 1Radboud University Medical CenterNCT02629874Written as EA-230
What changed recently
From the registry's own updates since Oct 15, 2026.